康辰藥業(603590.SH):子公司擬以2500萬美元投資優鋭開曼
格隆匯 11 月 23日丨康辰藥業(603590.SH)公佈,2020年11月23日,公司二級全資子公司上海康辰及此次交易共同投資人C-Bridge 19、嘉善優之鋭等(合稱“本輪投資人”),與交易標的優鋭開曼及其下屬子公司、優鋭開曼全體現有股東共同簽署了《Series D Preferred Shares Purchase Agreement》(“《股份認購協議》”),其中上海康辰擬以2500萬美元價格認購優鋭開曼新發行的5300.9334萬股D序列優先股。同時,為更好推動公司與優鋭開曼及其下屬子公司之間的業務合作,公司與優鋭開曼簽訂了《Cooperation Framework Agreement》(“《合作框架協議》”)。
此次增資完成後,上海康辰將持有優鋭開曼5300.9334萬股股份,約佔增資完成後優鋭開曼總股本(全面攤薄和轉股基礎上)的5.63%。
優鋭開曼設立於開曼羣島,主營業務為自有醫藥產品運營、授權醫藥產品上市和推廣、醫藥產品的推廣和銷售,主要聚焦手術鎮痛、呼吸疾病及補鐵劑三個領域,通過全資子公司Nuance Pharma Limited及二級全資子公司優鋭醫藥科技(上海)有限公司開展實際運營。
截至公告披露日,優鋭開曼經營主要產品信息如下:

優鋭開曼是一家高度整合的生物技術/專科藥公司,擁有領先的醫療和臨牀團隊,在海外原研藥引入等方面具有資源渠道優勢,其核心管理人員及銷售團隊具有多年進口藥品在中國國內商業運營經驗。本次交易有利於公司在原研藥開發、引入及商業化運營管理業務的拓展,通過與優鋭開曼及其核心團隊的緊密合作,提升公司醫藥產品引進的精準性,對公司未來在全球範圍內挖掘和引進新產品起到積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.